ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
A baseline systemic inflammatory signature predicts anti-PD-1 response in advanced melanoma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeReliable baseline biomarkers to predict response to immune checkpoint inhibitors (ICI) in advanced melanoma remain limited. We evaluated whether pre-treatment circulating inflammatory, hematologic, and molecular markers could identify patients most likely to benefit from anti-PD-1 therapy.
methodsIn this retrospective cohort study, 136 patients with unresectable stage III or metastatic stage IV melanoma treated with anti-PD-1-based immunotherapy were analyzed. Baseline plasma cytokines were quantified by cytometric bead array, hematologic parameters were obtained from routine blood counts, and molecular features were extracted from clinical records. Multivariable logistic regression was used to identify independent predictors of treatment response, and model discrimination was assessed by receiver operating characteristic analysis.
resultsResponders exhibited lower IL-6 levels, higher IL-10 levels, a lower IL-6/IL-10 ratio, higher erythrocyte counts, lower monocyte counts, greater PD-L1 positivity, and more frequent BRAF V600 mutations. In multivariable analysis, elevated monocyte counts (OR 4.57, 95% CI 1.67-13.86) and increased IL-6 levels (OR 2.70, 95% CI 1.08-7.21) independently predicted non-response, whereas higher IL-10 levels (OR 0.16, 95% CI 0.04-0.51) and BRAF V600 mutations (OR 0.32, 95% CI 0.13-0.76) predicted favorable response. The multivariable model demonstrated good discriminatory performance (AUC 0.783), with 82% sensitivity and 72% specificity.
conclusionsBaseline systemic inflammatory and hematologic biomarkers independently predict anti-PD-1 response in advanced melanoma. IMPACT: Readily accessible blood-based biomarkers may support treatment stratification and improve selection of patients most likely to benefit from immunotherapy. Prospective validation in independent cohorts is warranted.
Indexed as
Identifiers
42501206What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.